Abstract
Methods: Czech Republic belongs to countries that cover vaccination of adolescent women against HPV-16 and -18, which are associated with the development of cervical cancer, from general health insurance. There are two vaccines on the market, Cervarix and Silgard.
Both of them are highly effective against precancerosis and cancers related to HPV-16 and -18 infection. The quadrivalent vaccine Silgard further reduces the occurrence of genital warts because it elicits production of antibodies that are also effective against the non-onkogenic HPV-6 and -11.
The bivalent vaccine Cervarix has statistically significant cross protection against HPV-31, -33 and -45 and so it protects development of precancerosis and cancers associated with these viral genotypes. Conclusion: The incidence of cervical cancer in the Czech Republic is higher by comparison with the developed states of Europe.
HPV vaccination against the most risky HPV oncotypes may cause a significant reduction of cervical cancer in the HPV naive population.